NEW YORK — Pfizer Inc. plans to buy GlaxoSmithKline’s quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for about $130 million.

(NYSE: PFE) today announced that it has entered into an agreement with GlaxoSmithKline (GSK) to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for a total consideration of approximately $130 million (€115 million).

Pfizer said Monday that the deal will add two high-quality,  complementary vaccines to its portfolio, enabling the company to reach a broader global population.

Nimenrix is indicated for active immunization of people age 1 year and older against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y. Mencevax is indicated for active immunization of people older than 2 years against invasive meningococcal disease caused by meningococci of groups A, C, W-135 and Y.

Nimenrix is registered and approved for sale in 61 countries across the European Economic Area, Canada, Australia and emerging markets, with registrations under review in another 18 countries in Africa, Asia, Eastern Europe and the Middle East. Currently, Mencevax is registered and approved in 79 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.

With the 2014 approval of Trumenba (meningococcal group B vaccine) in the United States for protection against serogroup B meningococcal disease in people ages 10 to 25, the acquisition of NeisVac-C for protection against serogroup C meningococcal disease from Baxter last year, and the addition of the two GSK quadrivalent meningitis vaccines, Pfizer said it’s creating a broad portfolio focused on helping to prevent meningococcal disease as well as to control outbreaks.

“The addition of Nimenrix and Mencevax is an important milestone for Pfizer Vaccines. Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need — the prevention of meningococcal disease across all ages,” stated Susan Silbermann, president of Pfizer Vaccines. “Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis, an uncommon but serious and sometimes fatal disease. This helps us to further fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide and gives us even greater capability to meet the needs of the global community we serve.”

The transaction is expected to close in the second half of this year, pending customary closing conditions and regulatory approvals in several markets.